Based on the pharmacokinetics data for anti-murine ST2 (IgG-281) and anti-human ST2 (IgG-282) neutralizing antibodies aforementioned, a dose of 50 μg per injection was administered every 3 days for a total of 3–4 doses in the immunocompetent MLL-AF9 leukemia mice and humanized MOLM-14 NSG mice (Fig. 9C, M–O). The gene discussed is KMT2A; the disease is leukemia.